Preparation of your abstract

Below you will find information on how to prepare an abstract if you are an early or experienced healthcare professional or researcher.

Abstracts must be submitted in English. A “blind” selection process will be used. Features such as names of hospitals, medical schools, clinics or cities may not be listed in the title or text of the abstract.

  • The content of the abstract does not need to be original and can be previously published – however, this needs to be clearly indicated upon submission.
  • The abstract must be objective, substantive and not be of promotional nature.
  • Do not include the names of the authors in the abstract. Their names and affiliations (institutions/patient groups) will be registered separately when submitting the abstract online.
  • No late submissions will be accepted – should there be data that is revealed only after submission deadline, please inform the Summit Secretariat by emailing
  • The title should clearly indicate the nature of the study but should not be too long. Abbreviations cannot be used in the title. Please refrain from writing the title entirely in capital letters (e.g. NOT LIKE THIS).
  • The size of the abstract is limited to 2,000 characters (spaces and pictures are not included in the character count). Please note the submission tool on the website will automatically calculate the size of your abstract. It will not allow submissions that do not fit in the size requirements.

Ensure that your abstract includes the following:

  • Introduction & Objectives: A sentence describing the purpose of the study, case study or other.
  • Methodology: Describe your methodology in detail (the involvement of patients –if any – should be clearly highlighted in the methodology section).
  • Results: Describe your results in a logical sequence.
  • Conclusions: Emphasise new and important aspects and conclusions of the study, case study or other.

Please note the following:

  • If your abstract describes a case report, you can insert the whole text under the “Results” section.
  • Check spelling and grammar carefully.
  • Failure to comply with the following requirements will lead to automatic rejection of the submission:
    • Use generic names. The use of commercial drug names, brands and registered trademarks are strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.
    • Do not mention pharmaceutical company names in the abstract.

Submission Guidelines

  • Abstract submission deadline: TBC.
  • Abstracts will only be accepted through the online system.
  • The official Summit language is English; therefore abstracts need to be written in English.
  • The abstract should not exceed 2,000 characters (not including space and pictures).
  • Authors agree and accept publishing approved abstracts on the IPF summit website.
  • The sender of the abstract holds the responsibility of the contents being approved and authorised by other authors.
  • The authors have acknowledged any conflict of interests.
  • Only the first letters of each word in abstract title should be capital letter. Name and surname information should be clearly written, no abbreviation should be used.
  • After the submission is completed, the sender will receive a confirmation email to the address indicated at submission.
  • Only the abstracts sent for review (the submitter will have received a confirmation email) will be evaluated by the Scientific Steering Committee. Draft abstracts, which are not completed until the submission deadline, will be deleted.
  • After the evaluation is completed, the acceptance/rejection letters will be sent by email to the e-mail address indicated at submission.

Particular attention will be given to abstracts which include a patient perspective in their research. We accept any form of research including case reports, case studies and series, clinical trials, etc.

Evaluation Criteria

All submitted abstracts will be reviewed by two to three members of the Scientific Committee (including at least one HCP and one patient). A “blind” selection process will be used, meaning that information such as name of authors, hospitals, medical schools, clinics or cities may not be listed in the title or text of the abstract. Their names and affiliations (institutions) will be registered separately when submitting the abstract online.

Communication to participants

Acceptance letters will be sent via e-mail. Relevant information about your abstract’s presentation including the presentation date, time, venue, presentation number will be included in the acceptance letters.  The presenting author of the abstract must be registered for the congress.

On-site poster requirements

If a poster proposal is accepted by the Scientific Steering Committee, the exhibitor must arrive onsite with one (1) poster with the dimensions of A1 (594 x 841 mm) and following the standard format of: Abstract, Introduction, Methodology, Results, and Conclusion. Posters are not allowed to display sponsors’ logo’s. Selected authors are responsible for arranging their own poster and paying the registration fee.

All posters will be reviewed on-site at the Summit by the Scientific Committee.

Please note, that no European IPF Patient Summit funds are available for honoraria or to support participants’ travel.


The winning poster will be announced during the European IPF Patient Summit 2021.

There will be six awards:

For submissions by early and experienced healthcare professionals and researchers:

  • Best Research Poster
  • Best Person-Centred Care Poster
  • Best Policy & Advocacy Poster

For submissions by patients, patient representatives and support organisations

  • Best Research Poster
  • Best Person-Centred Care Poster
  • Best Policy & Advocacy Poster